Longboard Pharmaceuticals, Inc.

NasdaqGM:LBPH Stock Report

Market Cap: US$2.3b

Longboard Pharmaceuticals Valuation

Is LBPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LBPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LBPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LBPH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LBPH?

Key metric: As LBPH is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for LBPH. This is calculated by dividing LBPH's market cap by their current book value.
What is LBPH's PB Ratio?
PB Ratio8.5x
BookUS$275.19m
Market CapUS$2.33b

Price to Book Ratio vs Peers

How does LBPH's PB Ratio compare to its peers?

The above table shows the PB ratio for LBPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average10.6x
LGND Ligand Pharmaceuticals
2.7x35.5%US$2.3b
WVE Wave Life Sciences
16x38.1%US$2.2b
AMPH Amphastar Pharmaceuticals
2.9x6.7%US$2.2b
BLTE Belite Bio
20.7x69.4%US$2.5b
LBPH Longboard Pharmaceuticals
8.5x-7.6%US$2.3b

Price-To-Book vs Peers: LBPH is good value based on its Price-To-Book Ratio (8.5x) compared to the peer average (10.6x).

Price to Book Ratio vs Industry

How does LBPH's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.09xn/aUS$8.82m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.69m
UPC Universe Pharmaceuticals
0.1xn/aUS$3.04m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.44m
LBPH 8.5xIndustry Avg. 1.7xNo. of Companies28PB01.22.43.64.86+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: LBPH is expensive based on its Price-To-Book Ratio (8.5x) compared to the US Pharmaceuticals industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is LBPH's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LBPH PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio8.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LBPH's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LBPH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$59.91
US$64.67
+7.9%
11.5%US$80.00US$60.00n/a6
Nov ’25US$59.69
US$64.67
+8.3%
11.5%US$80.00US$60.00n/a6
Oct ’25US$37.09
US$65.88
+77.6%
23.8%US$90.00US$44.00n/a8
Sep ’25US$36.08
US$63.29
+75.4%
26.1%US$90.00US$40.00n/a7
Aug ’25US$32.92
US$55.63
+69.0%
35.1%US$90.00US$32.00n/a8
Jul ’25US$30.92
US$49.13
+58.9%
36.9%US$90.00US$32.00n/a8
Jun ’25US$18.87
US$42.00
+122.6%
26.6%US$60.00US$30.00n/a8
May ’25US$21.96
US$41.75
+90.1%
27.3%US$60.00US$30.00n/a8
Apr ’25US$21.05
US$42.57
+102.2%
28.0%US$60.00US$30.00n/a7
Mar ’25US$21.34
US$42.86
+100.8%
28.0%US$60.00US$30.00n/a7
Feb ’25US$21.15
US$43.33
+104.9%
29.8%US$60.00US$30.00n/a6
Jan ’25US$6.03
US$20.83
+245.5%
40.0%US$35.00US$11.00n/a6
Dec ’24US$4.00
US$20.00
+400.0%
40.6%US$35.00US$11.00n/a6
Nov ’24US$5.36
US$20.00
+273.1%
40.6%US$35.00US$11.00US$59.696
Oct ’24US$5.56
US$16.83
+202.8%
27.3%US$25.00US$11.00US$37.096
Sep ’24US$5.88
US$16.83
+186.3%
27.3%US$25.00US$11.00US$36.086
Aug ’24US$7.35
US$17.67
+140.4%
30.9%US$25.00US$11.00US$32.926
Jul ’24US$7.34
US$17.57
+139.4%
28.8%US$25.00US$11.00US$30.927
Jun ’24US$7.29
US$17.57
+141.0%
28.8%US$25.00US$11.00US$18.877
May ’24US$7.72
US$16.86
+118.4%
33.0%US$25.00US$11.00US$21.967
Apr ’24US$4.01
US$17.50
+336.4%
33.0%US$25.00US$11.00US$21.056
Mar ’24US$5.53
US$17.00
+207.4%
33.1%US$25.00US$11.00US$21.346
Feb ’24US$4.70
US$18.67
+297.2%
27.1%US$25.00US$11.00US$21.156
Jan ’24US$3.26
US$18.67
+472.6%
27.1%US$25.00US$11.00US$6.036
Dec ’23US$5.38
US$18.67
+247.0%
27.1%US$25.00US$11.00US$4.006
Nov ’23US$3.88
US$19.74
+408.7%
28.4%US$28.00US$12.00US$5.366

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

7D

6.8%

1Y

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

7D

6.1%

1Y

14.8%